IN2012DN02826A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02826A
IN2012DN02826A IN2826DEN2012A IN2012DN02826A IN 2012DN02826 A IN2012DN02826 A IN 2012DN02826A IN 2826DEN2012 A IN2826DEN2012 A IN 2826DEN2012A IN 2012DN02826 A IN2012DN02826 A IN 2012DN02826A
Authority
IN
India
Prior art keywords
day
weeks
amount
toxin
infusion
Prior art date
Application number
Other languages
English (en)
Inventor
John Lambert
James J O'leary
Joanne Elizabeth Sarah Schindler
Steven Weitman
Albert Qin
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of IN2012DN02826A publication Critical patent/IN2012DN02826A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2826DEN2012 2009-10-21 2010-10-21 IN2012DN02826A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25380409P 2009-10-21 2009-10-21
PCT/US2010/053579 WO2011050180A1 (en) 2009-10-21 2010-10-21 Novel dosing regimen and method of treatment

Publications (1)

Publication Number Publication Date
IN2012DN02826A true IN2012DN02826A (ja) 2015-07-24

Family

ID=43898626

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2826DEN2012 IN2012DN02826A (ja) 2009-10-21 2010-10-21

Country Status (13)

Country Link
US (1) US20110097345A1 (ja)
EP (1) EP2490715A4 (ja)
JP (1) JP2013508400A (ja)
KR (1) KR20120094472A (ja)
CN (1) CN102630165A (ja)
AU (1) AU2010310577A1 (ja)
BR (1) BR112012009250A2 (ja)
CA (1) CA2775806A1 (ja)
IL (1) IL219279A0 (ja)
IN (1) IN2012DN02826A (ja)
MX (1) MX2012004406A (ja)
RU (1) RU2012120691A (ja)
WO (1) WO2011050180A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
JP2013518053A (ja) * 2010-01-21 2013-05-20 イミュノジェン， インコーポレイテッド 卵巣癌の治療のための組成物および方法
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014052876A1 (en) * 2012-09-28 2014-04-03 Immunogen Inc. Methods for increasing efficacy of cd56- based therapy
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AU2014265587A1 (en) * 2013-05-14 2015-11-19 Immunogen Inc. Anti-FOLR1 immunoconjugate dosing regimens
SG10201907042PA (en) * 2013-10-08 2019-09-27 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
CN109803660A (zh) * 2016-08-10 2019-05-24 细胞基因公司 复发性和/或难治性实体瘤和非霍奇金淋巴瘤的治疗
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
KR20210061995A (ko) * 2018-06-26 2021-05-28 이뮤노젠 아이엔씨 Adam9를 표적으로 하는 면역콘쥬게이트 및 이를 이용하는 방법들
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP4161574A1 (en) * 2020-06-04 2023-04-12 BioInvent International AB Improving antibody tolerability associated with intravenous administration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1229934B1 (en) * 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2002305767B2 (en) * 2001-09-20 2008-04-10 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US7374762B2 (en) * 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
JP2006526662A (ja) * 2003-06-05 2006-11-24 アシュカル，チャールズ 過増殖性細胞疾患を治療する方法
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
RS59005B1 (sr) * 2006-09-26 2019-08-30 Genmab As Anti-cd38 plus kortikosteroidi plus nekortikosteroidni hemoterapeutik za tretiranje tumora
US8563700B2 (en) * 2008-06-16 2013-10-22 Immunogen, Inc. Synergistic effects
JP2013518053A (ja) * 2010-01-21 2013-05-20 イミュノジェン， インコーポレイテッド 卵巣癌の治療のための組成物および方法
WO2012138537A1 (en) * 2011-04-01 2012-10-11 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer

Also Published As

Publication number Publication date
IL219279A0 (en) 2012-06-28
JP2013508400A (ja) 2013-03-07
EP2490715A1 (en) 2012-08-29
CN102630165A (zh) 2012-08-08
MX2012004406A (es) 2012-05-08
RU2012120691A (ru) 2013-11-27
KR20120094472A (ko) 2012-08-24
EP2490715A4 (en) 2013-06-26
CA2775806A1 (en) 2011-04-28
BR112012009250A2 (pt) 2017-06-20
AU2010310577A1 (en) 2012-04-19
US20110097345A1 (en) 2011-04-28
WO2011050180A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
IN2012DN02826A (ja)
MY202279A (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
NZ625391A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EA033400B1 (ru) Антитело против cd3 и его применение
MX2018006844A (es) Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
EA201500019A1 (ru) Способ лечения gd2-положительного рака
NZ596807A (en) Uses of immunoconjugates targeting cd138
RU2011142281A (ru) Антитела к her
HK1120441A1 (en) Drugs for treatment of ovarian cancer
NZ604056A (en) Novel anti-cmet antibody
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
NZ603717A (en) Suture line administration technique using botulinum toxins
NZ588913A (en) Liver cancer drug
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2023001648A (es) Conjugado de anticuerpo y farmaco.
MY200161A (en) Bacteria for targeting tumors and treating cancer
AU2012253610A8 (en) Compositions and methods for treating cancer
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
CA2726050A1 (en) Achievement of high therapeutic index through molecular imaging guided targeted drug treatment
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
TW200727904A (en) Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine
MX2009004247A (es) Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento.